PLoS ONE (Jan 2023)

Risk of and duration of protection from SARS-CoV-2 reinfection assessed with real-world data.

  • Shannon L Reynolds,
  • Harvey W Kaufman,
  • William A Meyer,
  • Chris Bush,
  • Oren Cohen,
  • Kathy Cronin,
  • Carly Kabelac,
  • Sandy Leonard,
  • Steve Anderson,
  • Valentina Petkov,
  • Douglas Lowy,
  • Norman Sharpless,
  • Lynne Penberthy

DOI
https://doi.org/10.1371/journal.pone.0280584
Journal volume & issue
Vol. 18, no. 3
p. e0280584

Abstract

Read online

This retrospective observational study aimed to gain a better understanding of the protective duration of prior SARS-CoV-2 infection against reinfection. The objectives were two-fold: to assess the durability of immunity to SARS-CoV-2 reinfection among initially unvaccinated individuals with previous SARS-CoV-2 infection, and to evaluate the crude SARS-CoV-2 reinfection rate and associated risk factors. During the pandemic era time period from February 29, 2020, through April 30, 2021, 144,678,382 individuals with SARS-CoV-2 molecular diagnostic or antibody test results were studied. Rates of reinfection among index-positive individuals were compared to rates of infection among index-negative individuals. Factors associated with reinfection were evaluated using multivariable logistic regression. For both objectives, the outcome was a subsequent positive molecular diagnostic test result. Consistent with prior findings, the risk of reinfection among index-positive individuals was 87% lower than the risk of infection among index-negative individuals. The duration of protection against reinfection was stable over the median 5 months and up to 1-year follow-up interval. Factors associated with an increased reinfection risk included older age, comorbid immunologic conditions, and living in congregate care settings; healthcare workers had a decreased reinfection risk. This large US population-based study suggests that infection induced immunity is durable for variants circulating pre-Delta predominance.